Insider Sell: Cerevel Therapeutics Holdings Inc's Chief Human Resources Officer Sells Company Shares
Kenneth Dipietro, Chief Human Resources Officer of Cerevel Therapeutics Holdings Inc (NASDAQ:CERE), sold 6,256 shares of the company on December 20, 2023, according to a SEC Filing. Cerevel Therapeutics Holdings Inc is a biopharmaceutical company focused on developing drugs to treat disorders of the central nervous system, including schizophrenia and Parkinson's disease.
The transaction was executed at a price of $41.42 per share, resulting in a total value of $259,163.52. Following this transaction, the insider's stake in Cerevel Therapeutics Holdings Inc has been adjusted as per the latest SEC filings.
Over the past year, the insider has sold a cumulative total of 6,256 shares and has not made any purchases of the company's stock. This latest sale represents a continuation of the insider's selling pattern over the specified period.
The insider transaction history at Cerevel Therapeutics Holdings Inc reveals a trend of more insider sales than purchases over the past year. There have been 6 insider buys and 20 insider sells during this timeframe.
On the date of the insider's most recent transaction, shares of Cerevel Therapeutics Holdings Inc were trading at $41.42, giving the company a market capitalization of $7.568 billion.
Investors often monitor insider buy and sell activities as an indicator of a stock's future performance, although it is important to consider a wide array of factors when evaluating investment opportunities.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
